Now, several phase II clinical trials of APR-246 are ongoing, including a systemic carboplatin combination chemotherapy with APR-246 in patients with platinum sensitive recurrent high grade serous ovarian cancer with mutated p53 (NCT02098343), a combination of APR-246 with azacytidine in p53 mutant myeloid neoplasms (NCT03072043) and a combination of APR-246 with 5-FU and cisplatin in oesophageal cancer (NCT02999893). Here, TP53 is linked to myeloid neoplasm.